Kamila Czora-Poczwardowska

Mrs. Kamila Czora-Poczwardowska

Poznan University of Medical Sciences
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2021 in Behavioural Brain Research
Verified
Journal Article
Closed access
EGEwa Gibuła-Tarłowska
Ewa Gibuła-Tarłowska
VKVolker Korz
Volker Korz
MLMalgorzata Lopatynska-Mazurek
Malgorzata Lopatynska-Mazurek
ACAgnieszka Chlopas-Konowalek
Agnieszka Chlopas-Konowalek
PGPawel Grochecki
Pawel Grochecki
Jolanta H. KotlinskaJolanta H. Kotlinska
Jolanta H. Kotlinska

26 August 2024 in Biomolecules
Verified
Journal Article
Open access
PDF file
Joanna Bartkowiak-WieczorekJoanna Bartkowiak-Wieczorek
Joanna Bartkowiak-Wieczorek
Agnieszka BienertAgnieszka Bienert
Agnieszka Bienert
KCKamila Czora-Poczwardowska
Kamila Czora-Poczwardowska
Radosław KujawskiRadosław Kujawski
Radosław Kujawski
Michał SzulcMichał Szulc
Michał Szulc
Edyta MądryEdyta Mądry
Edyta Mądry
Introduction: Cannabis sativa L. (CSL) extract has pain-relieving potential due to its cannabinoid content, so the effects of two CSL extracts on alleviating neuropathic pain were investigated in vivo. Methods and groups: Male Wistar rats (n = 130) were divided into groups and received vincristine (0.1 mg/kg) and gabapentin (60 mg/kg) to induce and relieve neuropathic pain or CSL extracts (D and B). The mRNA and protein expression of the cannabinoid receptors type 1 and 2 (CB1R, CB2R) were evaluated in the cerebral cortex, hippocampus, and lymphocytes. Behavioural tests (Tail-Flick and von Frey) were performed on all animals. Results: VK-induced neuropathic pain was accompanied by decreased CB1R protein level and CB2R mRNA expression in the cortex. Gabapentin relieved pain and increased CB1R protein levels in the hippocampus compared to the vincristine group. Hippocampus CB1R protein expression increased with the administration of extract D (10 mg/kg, 40 mg/kg) and extract B (7.5 mg/kg, 10 mg/kg) compared to VK group. In the cerebral cortex CSL decreased CB1R protein expression (10 mg/kg, 20 mg/kg, 40 mg/kg of extract B) and mRNA level (5 mg/kg, 7.5 mg/kg of extract B; 20 mg/kg of extract D) compared to the VK-group.CB2R protein expression increased in the hippocampus after treatment with extract B (7.5 mg/kg) compared to the VK-group. In the cerebral cortex extract B (10 mg/kg, 20 mg/kg) increased CB2R protein expression compared to VK-group. Conclusion: Alterations in cannabinoid receptor expression do not fully account for the observed behavioural changes in rats. Therefore, additional signalling pathways may contribute to the initiation and transmission of neuropathic pain. The Cannabis extracts tested demonstrated antinociceptive effects comparable to gabapentin, highlighting the antinociceptive properties of Cannabis extracts for human use.

30 March 2023 in Nutrients
Verified
Journal Article
Open access
PDF file
Michał SzulcMichał Szulc
Michał Szulc
Radosław KujawskiRadosław Kujawski
Radosław Kujawski
APAmanda Pacholak
Amanda Pacholak
MPMarta Poprawska
Marta Poprawska
KCKamila Czora-Poczwardowska
Kamila Czora-Poczwardowska
Przemysław Łukasz MikołajczakPrzemysław Łukasz Mikołajczak
Przemysław Łukasz Mikołajczak
The study aimed to explore in vivo the influence of cannabidiol (CBD) on the development of alcohol tolerance in rats. Rats were treated with ethanol (3.0 g/kg, i.p.) and CBD (20 mg/kg, p.o.) for nine successive days, and rectal body temperature, sedation (sleeping time), and blood alcohol concentration (BAC) were measured. In the prefrontal cortex, hippocampus, and striatum, the cannabinoid (CB1R and CB2R) and dopaminergic (DRD1, DRD2, DRD4, DRD5) receptors’ mRNA level changes were analyzed using the quantitative RT-PCR method. CBD inhibited the development of tolerance to the hypothermic and sedative action of alcohol, coupled with BAC elevation. On a molecular level, the most pronounced effects of the CBD + ethanol interaction in the striatum were observed, where CBD reversed the downregulation of CB2R gene transcription caused by ethanol. For CB1R, DRD1, and DRD2 mRNAs, the CBD + ethanol interaction produced opposite effects than for CB2R ones. In turn, for the transcription of genes encoding dopaminergic receptors, the most potent effect of alcohol as CBD occurred in the hippocampus. However, the combined CBD and alcohol administration showed the same effect for each substance administered separately. Since tolerance is considered a prelude to drug addiction, obtained results allow us to emphasize the thesis that CBD can inhibit the development of alcohol dependence in rats.

24 December 2021 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
Michał SzulcMichał Szulc
Michał Szulc
Radosław KujawskiRadosław Kujawski
Radosław Kujawski
JBJustyna Baraniak
Justyna Baraniak
MKMałgorzata Kania-Dobrowolska
Małgorzata Kania-Dobrowolska
EKEwa Kamińska
Ewa Kamińska
Przemysław Łukasz MikołajczakPrzemysław Łukasz Mikołajczak
Przemysław Łukasz Mikołajczak
The study was carried out on alcohol-preferring male Wistar rats. The following drugs were repeatedly (28×) administered: acamprosate (500 mg/kg, p.o.), naltrexone (0.1 mg/kg, i.p), and Pueraria lobata (kudzu) root extract (KU) (500 mg/kg, p.o.) and its isoflavones: daidzin (40 mg/kg, p.o.) and puerarin (150 mg/kg, p.o.). Their effects on a voluntary alcohol intake were assessed. KU and alcohol were also given for 9 days in an experiment on alcohol tolerance development. Finally, total and active ghrelin levels in peripheral blood serum were measured by ELISA method. Acamprosate, naltrexone, daidzin, and puerarin, reducing the alcohol intake, caused an increase in both forms of ghrelin levels. On the contrary, though KU inhibited the alcohol intake and alcohol tolerance development, it reduced ghrelin levels in alcohol-preferring rats. The changes of ghrelin concentration could play a role as an indicator of the currently used drugs. The other effect on the KU-induced shift in ghrelin levels in the presence of alcohol requires further detailed study.

29 October 2022 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
Michał SzulcMichał Szulc
Michał Szulc
Radosław KujawskiRadosław Kujawski
Radosław Kujawski
Przemysław Łukasz MikołajczakPrzemysław Łukasz Mikołajczak
Przemysław Łukasz Mikołajczak
ABAnna Bogacz
Anna Bogacz
MWMarlena Wolek
Marlena Wolek
ASAgnieszka Seremak-Mrozikiewicz
Agnieszka Seremak-Mrozikiewicz
The aim of the study was to investigate the effect of baicalein or Scutellaria baicalensis root extract interaction with methyldopa in pregnant spontaneously hypertensive rats (SHR) at the pharmacodynamic, molecular, and biochemical levels. The rats, after confirming pregnancy, received baicalein (200 mg/kg/day, p.o.) and extract (1000 mg/kg/day, p.o.), in combination with methyldopa (400 mg/kg/day; p.o.), for 14 consecutive days, 1 h before blood pressure and heart rate measurements. In the heart and placenta from mothers after giving birth to their offspring, mRNA expression of factors related to inflammatory processes (TNF-α, Il-1β, IL-6) and vascular diseases (TGF-β, HIF-1α, VEGF, PlGF) was measured. Levels of markers of oxidative stress (superoxide dismutase and malondialdehyde) in the placenta and indicators of myocardial damage (troponin cTnC and cTnI, creatine kinase, myoglobin, and lactate dehydrogenase) in the heart were also assessed. Baicalein co-administered with methyldopa was associated with reduced blood pressure, especially during the first three days. The interactions were more pronounced for such factors as TGF-β, HIF-1α, VEGF, and PlGF than TNF-α, Il-1β, and IL-6. Combined application of baicalein and extract with methyldopa may be of value in the development of a new antihypertensive medication intended for patients suffering from preeclampsia or pregnancy-induced hypertension.

6 January 2025 in Molecules
Verified
Journal Article
Open access
PDF file
Joanna Bartkowiak-WieczorekJoanna Bartkowiak-Wieczorek
Joanna Bartkowiak-Wieczorek
Małgorzata JamkaMałgorzata Jamka
Małgorzata Jamka
Radosław KujawskiRadosław Kujawski
Radosław Kujawski
MHMarcin Holysz
Marcin Holysz
Agnieszka BienertAgnieszka Bienert
Agnieszka Bienert
Edyta MądryEdyta Mądry
Edyta Mądry
Inflammation is the critical component of neuropathic pain; therefore, this study aimed to assess the potential anti-inflammatory effects of Cannabis sativa L. extracts in a vincristine-induced model of neuropathic pain. The effects of different doses (5.0–40.0 mg/kg) of two Cannabis sativa L. extracts (B and D) on COX-1, COX-2, TNF-α, and NF-κB mRNA and protein levels were examined in the rat hippocampus, cerebral cortex, and blood lymphocytes. There were statistically significant differences in COX-1, COX-2, and TNF-α mRNA and protein expression in the hippocampus and cerebral cortex, with significant differences in COX-2 and TNF-α in the lymphocytes. Extract D dose-dependently increased COX-1 mRNA and protein in the hippocampus and cortex. In contrast, Extract B dose-dependently increased COX-1 mRNA and decreased COX-2 mRNA (in a dose of 7.5 mg/kg) and TNF-α protein levels in the cortex. Cannabis sativa L. extracts significantly influenced the expression of inflammatory genes and proteins, with effects varying based on dose and tissue type. The increased expression of COX-1, COX-2, and TNF-α (in comparison to groups receiving NaCl, vincristine, and gabapentin) in the rat hippocampus and COX-1 in the cerebral cortex suggests that Cannabis may have a pro-inflammatory effect. Due to species specificity, the results of our research based on rats require confirmation in humans. However, Cannabis sativa should be recommended with caution for treating pain with an inflammatory component.